ALPINE (NCT03734016) is a global, Phase 3, randomized trial comparing zanubrutinib with ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

SEQUOIA (NCT03336333) is a global Phase 3, open-label, randomized study of zanubrutinib versus bendamustine plus rituximab (B+R) in patients with previously untreated chronic lymphocytic leukemia (CLL).